دورية أكاديمية
Additive effects of resveratrol and doxorubicin on bladder cancer cells.
| العنوان: | Additive effects of resveratrol and doxorubicin on bladder cancer cells. |
|---|---|
| المؤلفون: | Soares LBM; Escola de Farmácia, Departamento de Análises Clínicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais., Lima APB; Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais., Melo AS; Escola de Farmácia, Departamento de Análises Clínicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais., Almeida TC; Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais., de Medeiros Teixeira LF; Escola de Farmácia, Departamento de Análises Clínicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais., da Silva GN; Escola de Farmácia, Departamento de Análises Clínicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais.; Programa de Pós-graduação em Ciências Farmacêuticas (CIPHARMA), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais.; Programa de Pós-graduação em Ciência Biológicas (CBIOL), Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil. |
| المصدر: | Anti-cancer drugs [Anticancer Drugs] 2022 Jan 01; Vol. 33 (1), pp. e389-e397. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 9100823 Publication Model: Print Cited Medium: Internet ISSN: 1473-5741 (Electronic) Linking ISSN: 09594973 NLM ISO Abbreviation: Anticancer Drugs Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Lippincott Williams & Wilkins Original Publication: Oxford, UK : Rapid Communications of Oxford, [1990- |
| مواضيع طبية MeSH: | Antineoplastic Agents/*pharmacology , Doxorubicin/*pharmacology , Resveratrol/*pharmacology , Urinary Bladder Neoplasms/*pathology, Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Survival/drug effects ; Dose-Response Relationship, Drug ; Doxorubicin/administration & dosage ; Humans ; Oxidative Stress/drug effects ; Resveratrol/administration & dosage ; Xenograft Model Antitumor Assays |
| مستخلص: | The treatment of bladder cancer remains a challenge in clinical practice. Different chemotherapeutic protocols can be used; however, it is common to observe tumor recurrence and secondary effects that result in toxicity. Doxorubicin (DOX), one of the most effective anticancer agents used to treat bladder cancer, can cause chronic cardiotoxicity, limiting its use in clinical practice. Resveratrol (RES), a natural product with potential antitumor activity against bladder cancer, is associated with rapid metabolism and low bioavailability and needs to be combined with chemotherapeutic drugs to improve its use. Our study aimed to assess the therapeutic effect of a low concentration of DOX (2 µM) in combination with RES (150, 200 and 250 µM) on two bladder cancer cell lines. We investigated the mechanism of interaction between the drugs by performing cytotoxicity, clonogenic, oxidative stress, cell migration, cell morphology and nuclear division index (NDI) assays. Cytotoxicity evaluation revealed an additive interaction between RES and DOX for both cell lines. Additionally, the results of cell colony formation, oxidative stress, cell migration, cell morphology and NDI assays showed that a combination of DOX and RES was more effective than RES or DOX alone. In conclusion, a low concentration of DOX combined with RES could potentiate the antitumor effects of the drugs on bladder cancer cells, thus overcoming the secondary effects caused by DOX and the low bioavailability of resveratrol. (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.) |
| References: | Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: an overview. Int J Cancer 2021; 149:778–789. Ulamec M, Murgić J, Novosel L, Tomić M, Terlević R, Tomašković I, et al. New Insights into the diagnosis, molecular taxonomy, and treatment of bladder cancer. Acta Med Acad 2021; 50:143–156. Facchini G, Cavaliere C, Romis L, Mordente S, Facchini S, Iovane G, et al. Advanced/metastatic bladder cancer: current status and future directions. Eur Rev Med Pharmacol Sci 2020; 24:11536–11552. Kaya AO, Coskun U, Ozkan M, Sevinc A, Yilmaz AU, Gumus M, et alAnatolian Society of Medical Oncology (ASMO). Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy. Onkologie 2012; 35:576–580. Johnson-Arbor K, Dubey R. Doxorubicin. 2021.StatPearls Publishing;. Butowska K, Woziwodzka A, Borowik A, Piosik J. Polymeric nanocarriers: a transformation in doxorubicin therapies. Materials (Basel) 2021; 14:2135. Al Refaey HR, Newairy AA, Wahby MM, Albanese C, Elkewedi M, Choudhry MU, Sultan AS. Manuka honey enhanced sensitivity of HepG2, hepatocellular carcinoma cells, for Doxorubicin and induced apoptosis through inhibition of Wnt/β-catenin and ERK1/2. Biol Res 2021; 54:16. Zhang N, Gao M, Wang Z, Zhang J, Cui W, Li J, et al. Curcumin reverses doxorubicin resistance in colon cancer cells at the metabolic level. j Pharm Biomed Anal 2021; 201:114129. Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, et al. The role of resveratrol in cancer therapy. Int j Mol Sci 2017; 18:E2589. Al-Abd AM, Mahmoud AM, El-Sherbiny GA, El-Moselhy MA, Nofal SM, El-Latif HA, et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro . Cell Prolif 2011; 44:591–601. Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 2014; 1840:615–625. Barros AS, Costa EC, Nunes AS, de Melo-Diogo D, Correia IJ. Comparative study of the therapeutic effect of Doxorubicin and Resveratrol combination on 2D and 3D (spheroids) cell culture models. Int j Pharm 2018; 551:76–83. Almeida TC, Guerra CCC, De Assis BLG, de Oliveira Aguiar Soares RD, Garcia CCM, Lima AA, da Silva GN. Antiproliferative and toxicogenomic effects of resveratrol in bladder cancer cells with different TP53 status. Environ Mol Mutagen 2019; 60:740–751. da Silva GN, de Castro Marcondes JP, de Camargo EA, da Silva Passos Júnior GA, Sakamoto-Hojo ET, Salvadori DM. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. Exp Biol Med (Maywood) 2010; 235:814–824. Pouyafar A, Heydarabad MZ, Aghdam SB, Khaksar M, Azimi A, Rahbarghazi R, Talebi M. Resveratrol potentially increased the tumoricidal effect of doxorubicin on SKOV3 cancer stem cells in vitro. J Cell Biochem 2018; 120:8430–8437. Sühnel J. Evaluation of synergism or antagonism for the combined action of antiviral agents. Antiviral Research 1990; 13:23–39. Huang Y, Zhou S, He C, Deng J, Tao T, Su Q, et al. Phenformin alone or combined with geftinib inhibits bladder cancer via AMPK and EGFR pathways. Cancer Commun 2018; 50:1–14. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 2010; 594:57–72. Fenech M. Cytokinesis-block micronucleus cytome assay. Nat Protoc 2007; 2:1084–1104. Barros TMB, Lima APB, Almeida TC, da Silva GN. Inhibition of urinary bladder cancer cell proliferation by silibinin. Environ Mol Mutagen 2020; 61:445–455. Sávio AL, da Silva GN, Salvadori DM. Inhibition of bladder cancer cell proliferation by allyl isothiocyanate (mustard essential oil). Mutat Res 2015; 771:29–35. Lima APB, Almeida TC, Barros TMB, Rocha LCM, Gargia CCM, Silva GN. Toxicogenetic and antiproliferative effects of chrysin in urinary bladder cancer cells. Mutagenesis 2020; 35361–371. Dudka J, Gieroba R, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, et al. Different effects of resveratrol on dose-related Doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med 2012; 2012:606183. Smolensky D, Rathore K, Cekanova M. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro . bmc Cancer 2015; 15:927. Osman AM, Bayoumi HM, Al-Harthi SE, Damanhouri ZA, Elshal MF. Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line. Cancer Cell Int 2012; 12:47. Lee JH, Wendorff TJ, Berger JM. Resveratrol: a novel type of topoisomerase II inhibitor. j Biol Chem 2017; 292:21011–21022. Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol 2019; 25:101084. Baribeau S, Chaudhry P, Parent S, Asselin É. Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One 2014; 9:e86987. Freitas JT, Jozic I, Bedogni B. Wound healing assay for melanoma cell migration. Methods Mol Biol 2021; 2265:65–71. Bai Y, Wang Y, Liu M, Gu YH, Jiang B, Wu X, Wang HL. Suppression of nuclear factor erythroid-2-related factor 2-mediated antioxidative defense in the lung injury induced by chronic exposure to methamphetamine in rats. Mol Med Rep 2017; 15:3135–3142. Zhao Y, Tang H, Zeng X, Ye D, Liu J. Resveratrol inhibits proliferation, migration and invasion via Akt and ERK1/2 signaling pathways in renal cell carcinoma cells. Biomed Pharmacother 2018; 98:36–44. Jin X, Wei Y, Liu Y, Lu X, Ding F, Wang J, Yang S. Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/β-catenin signaling pathway in breast cancer. Cancer Med 2019; 8:1246–1257. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 80168379AG (Doxorubicin) Q369O8926L (Resveratrol) |
| تواريخ الأحداث: | Date Created: 20210906 Date Completed: 20220202 Latest Revision: 20230902 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1097/CAD.0000000000001218 |
| PMID: | 34486536 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1473-5741 |
|---|---|
| DOI: | 10.1097/CAD.0000000000001218 |